TKI Inhibitors
Oct 19, 2026
Osteosarcoma Treatment Landscape: Can New Therapies Break a 40-Year Stalemate in Bone Cancer Care?
Summary Osteosarcoma is a rare, aggressive primary bone cancer that primarily affects adolescents and young adults. The total incident population across the seven major markets reached approximately 2,200 cases in 2025. In the United States, Acrotech Biopharma’s Levoleucovorin (KHAPZORY) has received FDA ap...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
